• Polygodial (SKU B7311) for TRPA1 Assays

  2026-09-24

  A practical guide to using Polygodial (SKU B7311) in TRPA1 and cell-based experiments, with safeguards for interpreting viability, calcium, and inflammatory readouts. It distinguishes product specifications from literature findings and offers workflow and vendor-selection considerations for reproducible research.

• Exemestane: Interpreting Aromatase Inhibition

  2026-09-23

  Exemestane is a steroidal aromatase inhibitor whose irreversible action makes assay design and endpoint interpretation especially important. This article explains how to distinguish target inactivation from downstream estrogen responses and how to use that distinction in breast cancer research.

• BRD4770: Reliable G9a Inhibition in Cell Assays

  2026-09-23

  This scenario-based guide explains how BRD4770 (SKU B4837) can support interpretable proliferation, viability, and senescence experiments through G9a inhibition and reduced H3K9 methylation. It also addresses formulation limits, dose optimization, orthogonal readouts, cross-model interpretation, and practical product-selection criteria.

• AT-406 (SM-406): From IAP Binding to Cell Death

  2026-09-22

  AT-406 (SM-406) is an orally bioavailable IAP antagonist for investigating how IAP inhibition, caspase-8 regulation, and PARP cleavage converge on cancer-cell death. This article presents a structure-informed framework for interpreting apoptosis assays, chemosensitization studies, and xenograft data.

• OCT2 and MATE1 Inhibition by Antiemetic Drugs

  2026-09-22

  George et al. systematically compared five 5-HT3 antagonists for inhibition of the renal organic cation transporters OCT2 and MATE1, combining transporter-overexpressing cells with a polarized transcellular model. The study identifies strong, transporter-selective differences in potency and shows that ondansetron can increase intracellular cation accumulation, supporting a mechanistic basis for drug–drug interactions involving renal secretion.

• CAY10499 for Lipid-Linked Cell Assay Design

  2026-09-21

  A scenario-based guide to using CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, as a mechanistic control in lipid-metabolism and cell-assay workflows. It explains assay compatibility, solvent handling, interpretation limits, and selection considerations for SKU B7841.

• AMG 487: A Context-Aware CXCR3 Tool

  2026-09-21

  AMG 487 is a selective CXCR3 antagonist for dissecting chemokine signaling, migration, calcium flux, and macrophage-state transitions. This article explains how inflammatory context and LAMP1-linked autophagy determine the meaning of CXCR3 inhibition in advanced assays.

• WRN–MMR Synthetic Lethality in MSI Colorectal Cancer

  2026-09-20

  This PNAS study defines a p53/PUMA-dependent apoptotic mechanism that explains why mismatch repair-deficient, microsatellite-instable colorectal cancer cells are selectively vulnerable to Werner helicase loss. Genetic depletion, rescue experiments, and xenograft models support WRN as a context-dependent therapeutic target, while the pharmacological data illustrate how RecQ helicase probes can be evaluated in genotype-matched cancer models.

• Targeted Non-Viral Gene Delivery to Adipocytes

  2026-09-19

  The reference study introduced ATS-9R as a fusion oligopeptide that combines adipocyte recognition through Prohibitin with a nona-arginine nucleic-acid delivery domain. In obese mice, an ATS-9R/shFABP4 complex enabled adipocyte-directed gene silencing, metabolic recovery, and more than 20% body-weight reduction, establishing a foundation for targeted non-viral delivery in obesity research.

• TRPV4-to-Assay Translation with Rabbit IgG Detection

  2026-09-18

  A translational framework linking TRPV4–P2X purinergic signaling in cough hypersensitivity with rigorous, reproducible rabbit IgG immunodetection across Western blotting, ELISA, IHC, and immunocytochemistry.

• Gemcitabine HCl in MRI-Guided Tumor Studies

  2026-09-18

  Connect nanomolar cell-killing data with longitudinal, anatomy-resolved tumor measurements in pancreatic cancer models. This workflow uses Gemcitabine HCl to align cytotoxicity testing, treatment scheduling, and multianimal MRI while separating biological response from measurement variability.

• AMG 487: A Practical CXCR3 Antagonist Workflow

  2026-09-17

  AMG 487 enables receptor-focused analysis of CXCR3 signaling across chemotaxis, calcium flux, and macrophage polarization. This guide translates the CXCL10–CXCR3–LAMP1 findings into state-aware assay workflows, controls, and troubleshooting decisions.

• Nutlin-3a: Reframing MDM2–p53 Translation

  2026-09-17

  Nutlin-3a is more than a conventional MDM2 inhibitor: it is a pharmacological probe for testing how p53 state, ferroptotic vulnerability, migration, and tumor-cell survival intersect. This article translates evidence from glioblastoma biology into a disciplined experimental strategy while clarifying where the data support a hypothesis—and where they do not yet justify a therapeutic conclusion.

• Dabigatran Etexilate: Assay-Ready Thrombin Biology

  2026-09-16

  Dabigatran etexilate is an oral prodrug and direct thrombin inhibitor with important implications for translational coagulation assays. This guide connects its activation chemistry, thrombin inhibition mechanism, clotting endpoints, and practical handling decisions for research workflows.

• One-step TUNEL Cy3 Apoptosis Detection Kit

  2026-09-16

  Map apoptotic DNA fragmentation in tissue sections or cultured cells with a Cy3-based workflow designed for microscopy and flow cytometry. Practical controls, assay parameters, and troubleshooting guidance help distinguish genuine treatment-associated apoptosis from preparation artifacts.

8022 records 1/535 page Next 12345 下5页 Last page